Clinical data from investigator-initiated trials in 20 patients with multiple autoimmune diseases show allogeneic CAR-T QT-019B was generally well tolerated and demonstrated encouraging efficacy –– QT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback